CONTENTS:
- Chronic obstructive pulmonary disease in heroin users: An underappreciated issue with clinical ramifications. Darke S., Farrell M., Duflou J., Lappin J., p. 1153-1155.
- Beyond 'single customer view': Player tracking's potential role in understanding and reducing gambling-related harm [Addiction opinion and debate]. Newall P., Swanton T.B., p. 1156-1163.
- Redefining harm: The role of data integration in understanding gambling behaviour. Muggleton N., p. 1164-1165.
- The benefits and challenges of online player tracking. Delfabbro P., p. 1166-1167.
- Player tracking in itself may not be enough for efficient reduction of gambling harm, but combined with a personal gambling license could provide new possibilities to tracking gambling-related harm. Nikkinen J., p. 1168-1169.
- Strengthening oversight and integrity: The multi-faceted role of centralized player tracking systems in gambling. Allami Y., p. 1170-1171.
- Stakeholders cannot simply wait for the gambling evidence-base to develop: We must all help to build it. Newall P., Swanton T.B., p. 1172-1173.
- The risk relationships between alcohol consumption, alcohol use disorder and alcohol use disorder mortality: A systematic review and meta-analysis. Carr T., Kilian C., Llamosas-Falcon L., Zhu Y., Lasserre A.M., Puka K., et al., p. 1174-1187.
- Incremental net monetary benefit of using varenicline for smoking cessation: A systematic review and meta-analysis of economic evaluation studies. Chaisai C., Patikorn C., Thavorn K., Lee S.W.H., Chaiyakunapruk N., Veettil S.K., p. 1188-1202.
- Impact of the disruption in supply of varenicline since 2021 on smoking cessation in England: A population study. Jackson S.E., Brown J., Tattan-Birch H., Shahab L., p. 1203-1210.
- Prazosin and cyproheptadine in combination in the treatment of alcohol use disorder: A randomized, double-blind, placebo-controlled trial. Aubin H.J., Berlin I., Guiraud J., Bruhwyler J., Batel P., Perney P., et al., p. 1211-1223.
- Commentary on Aubin et al.: Could combination medication approaches target mental health comorbidity in the context of alcohol use disorder? Arunogiri S., Morley K.C., p. 1224-1225.
- Alcohol drinking, DNA methylation and psychiatric disorders: A multi-omics Mendelian randomization study to investigate causal pathways. Shi X., Li M., Yao J., Li M.D., Yang Z., p. 1226-1237.
- Can a health warning label diminish the persuasive effects of health-oriented nutrition advertising on ready-to-drink alcohol product packaging? A randomized experiment. Hobin E., Thielman J., Forbes S.M., Poon T., Bélanger-Gravel A., Demers-Potvin É., et al., p. 1238-1252.
- Associations between child maltreatment and hospital admissions for alcohol and other substance use-related disorders up to 40 years of age: Results from the Childhood Adversity and Lifetime Morbidity study. Bull C., Trott M., Najman J.M., Arnautovska U., Siskind D., Warren N., et al., p. 1253-1263.
- The prevalence of substance use disorders among people in Norwegian, Danish and Swedish prisons: A multi-national cohort study, 2010-19. Bukten A., Virtanen S., Hesse M., Thylstrup B., Kvamme T.L., Seid A.K., et al., p. 1264-1275.
- Integrated care van delivery of evidence-based services for people who inject drugs: A cluster-randomized trial. Page K.R., Weir B.W., Zook K., Rosecrans A., Harris R., Grieb S.M., et al., p. 1276-1288.
- Empirically contrasting urine drug screening-based opioid use disorder treatment outcome definitions. Brandt L., Odom G.J., Hu M.C., Castro C., Balise R.R., p. 1289-1300.
- Broad evidence of xylazine in the UK illicit drug market beyond heroin supplies: Triangulating from toxicology, drug-testing and law enforcement. Copeland C.S., Rice K., Rock K.L., Hudson S., Streete P., Lawson A.J., et al., p. 1301-1309.
- Commentary on Copeland et al.: Does xylazine in the United Kingdom foreshadow a European synthetic polysubstance drug crisis? Friedman J.R., p. 1310-1312.
- Target trial emulation for comparative effectiveness research with observational data: Promise and challenges for studying medications for opioid use disorder. Christine P.J., Lodi S., Hsu H.E., Bovell-Ammon B., Yan S., Bernson D., et al., p. 1313-1321.
- Addiction Lives: Robert West. Berridge V., p. 1322-1323.
- Gambling advertising still exists in Belgium despite a widely reported 'ban'. De Jans S., Hudders L., Newall P., p. 1324-1326.
- 'Return to player' information given to gamblers is unintuitive, misleading and often incorrect. Palomäki J., Kunnari A., Laakasuo M., p. 1327-1328.